Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Predictive factors for recurrence and survival in hepatocellular carcinoma in South Korea.

Jun CH, Sim DW, Kim SH, Hong HJ, Chung MW, Myoung E, Koh HR, Cho SB, Kim HS, Choi SK, Rew JS.

Anticancer Res. 2013 Sep;33(9):4129-34.

PMID:
24023360
2.

Preoperative predictors of microvascular invasion in multinodular hepatocellular carcinoma.

Zhao WC, Fan LF, Yang N, Zhang HB, Chen BD, Yang GS.

Eur J Surg Oncol. 2013 Aug;39(8):858-64. doi: 10.1016/j.ejso.2013.04.003. Epub 2013 May 11.

PMID:
23669199
3.

[Evaluation of prognosis and recurrence of hepatocellular carcinoma treated from 1988 to 2002 at Department of Medicine III, Kyushu University Hospital].

Arimura E, Nakamuta M, Kotoh K, Morizono S, Fukutomi M, Ohta S, Enjoji M, Sakai H, Nawata H.

Fukuoka Igaku Zasshi. 2004 Aug;95(8):195-200. Japanese.

PMID:
15552961
4.

Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.

Hu HT, Kim JH, Lee LS, Kim KA, Ko GY, Yoon HK, Sung KB, Gwon DI, Shin JH, Song HY.

J Vasc Interv Radiol. 2011 Jul;22(7):917-23. doi: 10.1016/j.jvir.2011.03.005. Epub 2011 May 14.

PMID:
21571545
5.

Tumor size does not independently affect long-term survival after curative resection of solitary hepatocellular carcinoma without macroscopic vascular invasion.

Zhang H, Yuan SX, Dai SY, Zhang JM, Huang X, Lu CD, Lu JH, Wu FQ, Lau WY, Wu MC, Yang T, Shen F.

World J Surg. 2014 Apr;38(4):947-57. doi: 10.1007/s00268-013-2365-2.

PMID:
24258262
6.
7.

Risk factors for patients with stage IVB hepatocellular carcinoma and extension into the heart: prognostic and therapeutic implications.

Jun CH, Sim DW, Kim SH, Hong HJ, Chung MW, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS.

Yonsei Med J. 2014 Mar;55(2):379-86. doi: 10.3349/ymj.2014.55.2.379.

8.

A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.

Lladó L, Virgili J, Figueras J, Valls C, Dominguez J, Rafecas A, Torras J, Fabregat J, Guardiola J, Jaurrieta E.

Cancer. 2000 Jan 1;88(1):50-7.

PMID:
10618605
9.

Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study.

Wang C, Lu Y, Chen Y, Feng Y, An L, Wang X, Su S, Bai W, Zhou L, Yang Y, Xu D.

Clin Exp Metastasis. 2009;26(7):839-48. doi: 10.1007/s10585-009-9283-6.

PMID:
19784786
10.

[Long term (5 years) outcome of radiofrequency ablation for hepatocellular carcinoma in 256 cases].

Chen MH, Yan K, Yang W, Gao W, Dai Y, Huo L, Zhang H, Huang XF.

Beijing Da Xue Xue Bao. 2005 Dec 18;37(6):671-2. Chinese.

11.

Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.

An HJ, Jang JW, Bae SH, Choi JY, Yoon SK, Lee MA, You YK, Kim DG, Jung ES.

Liver Transpl. 2012 Dec;18(12):1406-14. doi: 10.1002/lt.23512.

12.

Predictors and patterns of recurrence after resection of hepatocellular carcinoma.

Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP.

J Am Coll Surg. 2003 Nov;197(5):753-8.

PMID:
14585409
13.

Prognostic factors and optimal treatment strategy for intrahepatic nodular recurrence after curative resection of hepatocellular carcinoma.

Choi GH, Kim DH, Kang CM, Kim KS, Choi JS, Lee WJ, Kim BR.

Ann Surg Oncol. 2008 Feb;15(2):618-29. Epub 2007 Nov 15.

PMID:
18004628
14.

C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion.

Kim JM, Kwon CH, Joh JW, Ko JS, Park JB, Lee JH, Kim SJ, Paik SW, Park CK.

World J Surg Oncol. 2013 Apr 23;11:92. doi: 10.1186/1477-7819-11-92.

15.

Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection.

Shim JH, Kim KM, Lee YJ, Ko GY, Yoon HK, Sung KB, Park KM, Lee SG, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ.

Ann Surg Oncol. 2010 Mar;17(3):869-77. doi: 10.1245/s10434-009-0788-7. Epub 2009 Dec 22.

PMID:
20033326
16.

Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma.

Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST.

J Gastrointest Surg. 2008 Jan;12(1):183-91. Epub 2007 Sep 15.

PMID:
17874276
17.

Predictors of long-term survival in hepatocellular carcinomas: A longitudinal follow-up of 108 patients with small tumors.

Chang HC, Lin YM, Yen AM, Chen SL, Wu WY, Chiu SY, Fann JC, Lin YS, Chen HH, Liao CS.

Anticancer Res. 2013 Nov;33(11):5171-8.

PMID:
24222166
18.

Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy.

Pompili M, Rapaccini GL, Covino M, Pignataro G, Caturelli E, Siena DA, Villani MR, Cedrone A, Gasbarrini G.

Cancer. 2001 Jul 1;92(1):126-35.

PMID:
11443618
19.
20.

Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy.

Lin ZZ, Hsu C, Hu FC, Shao YY, Chang DY, Yang CH, Hong RL, Hsu CH, Cheng AL.

Oncologist. 2012;17(7):970-7. doi: 10.1634/theoncologist.2011-0411. Epub 2012 Jun 6.

Supplemental Content

Support Center